Home » Newsletters » BioWorld Science

BioWorld Science

July 16, 2020

View Archived Issues

RNA editing restores Rett protein

Single-cell studies give insights into pulmonary fibrosis

CD63 expression confers poor survival in patients with ESCC

Starvation safety switch could make cell therapies safer

Discovery of PQR-626, a potent and brain-penetrant mTOR inhibitor

HLJ1 as a potential new therapeutic target and biomarker in HCC

Intra-Cellular Therapies identifies 5-HT2A, mu-opioid, dopamine D1 and D2 receptor ligands

New RIP-2 inhibitors discovered at Celgene

KSQ Therapeutics presents new ubiquitin carboxyl-terminal hydrolase 1 inhibitors

RCC2 blockade is a potential therapeutic approach in glioblastoma

Sage Therapeutics describes GABA-A receptor modulators

Roche patents antibacterials

First child dosed in phase II study of infigratinib in achondroplasia

Novocure and MSD to study Tumor Treating Fields with Keytruda in NSCLC

Can-Fite amends phase II COVID-19 study protocol based on FDA guidance

Byondis initiates phase II study of SYD-985 in advanced endometrial cancer

Zydus begins human dosing with ZyCoV-D vaccine

CS-3003, an HDAC6 inhibitor, shows promise for treating multiple myeloma

FDA clears IND for clinical evaluation of long-acting human IL-7 NT-17 for mild COVID-19

RBM-007 enters phase I study for treatment of achondroplasia

Octapharma reports on use of Octagam IVIG in critically ill patients with COVID-19

BioAegis cleared to begin phase II study of rhu-pGSN in severe COVID-19 pneumonia

Bold Therapeutics reports promising in vitro data on BOLD-100 for COVID-19

Phase II study of GT-005 begins enrolling patients with GA secondary to AMD

First-in-human study of SL-172154 in ovarian cancer starts

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...